{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T21:57:55Z","timestamp":1790287075082,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82073872"],"award-info":[{"award-number":["82073872"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273771"],"award-info":[{"award-number":["82273771"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473765"],"award-info":[{"award-number":["82473765"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.bmcl.2025.130495","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T17:26:30Z","timestamp":1765473990000},"page":"130495","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Design, synthesis and biological evaluation of ALK\/HDAC dual-targeting agents"],"prefix":"10.1016","volume":"133","author":[{"given":"Ye","family":"Kong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shunda","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xintong","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiping","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiwei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingjie","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2025.130495_bb0005","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2024.07.009","article-title":"Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: real-world outcomes from the guardant INFORM database","volume":"19","author":"Parikh","year":"2024","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bmcl.2025.130495_bb0010","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/med.21750","article-title":"Molecular targeting therapies for neuroblastoma: Progress and challenges","volume":"41","author":"Zafar","year":"2021","journal-title":"Med Res Rev"},{"key":"10.1016\/j.bmcl.2025.130495_bb0015","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/cac2.12038","article-title":"Association of an anaplastic lymphoma kinase pathway signature with cell de-differentiation, neoadjuvant chemotherapy response, and recurrence risk in breast cancer","volume":"40","author":"Liu","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"10.1016\/j.bmcl.2025.130495_bb0020","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1530\/ERC-20-0436","article-title":"Targeting EML4-ALK gene fusion variant 3 in thyroid cancer","volume":"28","author":"Aydemirli","year":"2021","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bmcl.2025.130495_bb0025","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1158\/1541-7786.MCR-20-0738","article-title":"Preclinical evaluation of gilteritinib on NPM1-ALK-driven anaplastic large cell lymphoma cells","volume":"19","author":"Kuravi","year":"2021","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130495_bb0030","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/s43018-023-00515-0","article-title":"ALK-positive lung cancer: a moving target","volume":"4","author":"Schneider","year":"2023","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bmcl.2025.130495_bb0035","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1038\/s41571-022-00639-9","article-title":"Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management","volume":"19","author":"Cooper","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.bmcl.2025.130495_bb0040","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1038\/s41419-024-07272-7","article-title":"Targeting ERBB3 and AKT to overcome adaptive resistance in EML4-ALK-driven non-small cell lung cancer","volume":"15","author":"Sampson","year":"2024","journal-title":"Cell Death Dis"},{"issue":"3","key":"10.1016\/j.bmcl.2025.130495_bb0045","doi-asserted-by":"crossref","first-page":"615","DOI":"10.21037\/tlcr-22-708","article-title":"Strategies to overcome resistance to ALK inhibitors in non-small cell lung cancer: a narrative review","volume":"12","author":"Desai","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130495_bb0050","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1038\/s43018-022-00399-6","article-title":"Analysis of lorlatinib analogs reveals a roadmap for targeting diverse compound resistance mutations in ALK-positive lung cancer","volume":"3","author":"Shiba-Ishii","year":"2022","journal-title":"Nat Cancer"},{"key":"10.1016\/j.bmcl.2025.130495_bb0055","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrc.2017.84","article-title":"Understanding and targeting resistance mechanisms in NSCLC","volume":"17","author":"Rotow","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmcl.2025.130495_bb0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2022.02.001","article-title":"Dramatic response to brigatinib in a lung adenocarcinoma patient harboring EML4-ALK fusion and a G1202R de novo gene mutation","volume":"165","author":"Pan","year":"2022","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.bmcl.2025.130495_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2022.110264","article-title":"EML4-ALK G1202R mutation induces EMT and confers resistance to ceritinib in NSCLC cells via activation of STAT3\/Slug signaling","volume":"92","author":"Shen","year":"2022","journal-title":"Cell Signal"},{"key":"10.1016\/j.bmcl.2025.130495_bb0070","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.bmcl.2025.130495_bb0075","article-title":"Histone deacetylase complexes: structure, regulation and function","volume":"2024","author":"Asmamaw","year":"1879","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.bmcl.2025.130495_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116696","article-title":"Overview of class I HDAC modulators: inhibitors and degraders","volume":"276","author":"Huang","year":"2024","journal-title":"Eur J Med Chem."},{"key":"10.1016\/j.bmcl.2025.130495_bb0085","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1158\/0008-5472.CAN-18-2052","article-title":"Epithelial-to-mesenchymal transition is a mechanism of ALK inhibitor resistance in lung cancer independent of ALK mutation status","volume":"79","author":"Fukuda","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.bmcl.2025.130495_bb0090","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16213565","article-title":"Panobinostat synergizes with chemotherapeutic agents and improves efficacy of standard-of-care chemotherapy combinations in Ewing sarcoma cells","volume":"16","author":"Smith","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.bmcl.2025.130495_bb0095","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1111\/cas.15958","article-title":"Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer","volume":"114","author":"Ando","year":"2023","journal-title":"Cancer Sci"},{"key":"10.1016\/j.bmcl.2025.130495_bb0100","doi-asserted-by":"crossref","first-page":"17207","DOI":"10.1021\/acs.jmedchem.4c01098","article-title":"Syntheses of LSD1\/HDAC inhibitors with demonstrated efficacy against colorectal cancer: in vitro and in vivo studies including patient-derived organoids","volume":"67","author":"Chou","year":"2024","journal-title":"J Med Chem"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004044?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X25004044?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T08:22:44Z","timestamp":1781943764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X25004044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":20,"alternative-id":["S0960894X25004044"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130495","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Design, synthesis and biological evaluation of ALK\/HDAC dual-targeting agents","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2025.130495","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"130495"}}